OpenAI CFO says will be public in 2027 or sooner, CNBC reports
Newsquawk Staff ·
OpenAI CFO says will be public in 2027 or sooner, CNBC reports.
What it means
On-record IPO timing from a CFO is a stronger signal than the anonymous-sourcing that usually precedes large private listings, and finance chiefs in this position have historically used such remarks to begin conditioning investors and employees ahead of any formal process. The framing '2027 or sooner' is typical of pre-IPO messaging: a window wide enough to preserve optionality while establishing intent, with the actual sequence in comparable episodes being banking appointments, financial disclosure preparation, and only then a filing. OpenAI's case carries unusual complications that past mega-listings did not, including its corporate structure and the scale of private capital already absorbed, both of which bear on float size, index eligibility, and the eventual shareholder register. For listed comparables, the relevant channel is read-through to strategic partners with equity or revenue exposure, where private-market marks have previously re-rated on IPO confirmation. Follow-ons worth noting are any engagement of advisers, restructuring of the corporate form, audited financial disclosure, and secondary-market pricing in the shares, each of which has tended to tighten the timeline in prior episodes of this kind. As a statement of intent rather than a filing, the signal is directional and the calendar remains soft.
Sources
- Newsquawk Daily European Opening News - 23rd October 2026
- Tesla (TSLA) has decided not to proceed with plans to produce Cybertruck for Australia and New Zealand
- OpenAI trims valuation target to USD 1.25tln after previously pitching a higher price, according to FT
- OpenAI is raising up to USD 30bln in funding round at a USD 1.25tln valuation, led by UAE investors, according to CNBC, citing sources; OpenAI is negotiating a commercial deal that would secure more computing capacity from the UAE
- Merck & Co (MRK) and Moderna (MRNA) say safety profile of Intismeran plus Keytruda was generally consistent with previously reported studies of combination; significantly reduced the risk of recurrence or death by 42% compared to Keytruda alone
Related headlines
- Moderna (MRNA) downside attributed to early data leaks (link below) - UNCONFIRMED16 hours ago
- State of Rhode Island sues Meta (META) over alleged tolerance for scam advertising16 hours ago
- Nvidia (NVDA) launches Minerva platform for end-to-end AI factory observability17 hours ago
- US EQUITY OPEN: Mag-7 earnings lead Tech and Indices lower as the Middle East situation remains fragile19 hours ago
- Meta's (META) 5yr CDS hits an all-time high at 114.5bps19 hours ago
- Google (GOOGL) is launching an agent compute engine19 hours ago
- Citi (C) has been granted approval by China for its securities unit38 min ago
- Newmont (NEM) says production growth is expected to begin in 2027 following previously flagged 2026 trough, adds Q3 gold production was broadly flat sequentially as anticipated11 hours ago
- Western Digital (WDC) Q1 2027 (USD): Adj. EPS 4.64 (exp. 4.08), Revenue 4.38bln (exp. 4.14bln)12 hours ago
- Uber (UBER) puts all 30,000 employees on ChatGPT Work16 hours ago
- Newsquawk Daily US Earnings Estimates - 23rd October 2026: AXP16 hours ago
- Fireblocks denies talks with Visa (V), CoinDesk reports18 hours ago
- Norfolk Southern (NSC) says tightening truck capacity is improving rail competitiveness, supporting truck-to-rail conversions and stronger customer demand18 hours ago
- Procter & Gamble (PG) CFO says 'so far, consumer has held up, we don't know if that's going to continue'19 hours ago
- eBay (EBAY) confirms plans to reduce workforce by 9%; expects Q3 results above guidance 19 hours ago